January 12, 2022
The biosimilar entry for Takeda Pharmaceutical’s inflammatory bowel disease (IBD) treatment Entyvio (vedolizumab) in the US is expected to be three to five years later than the company’s previous assumption of May 2026, according to CEO Christophe Weber. Mr Weber...read more